Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2-Reference-Cited by-同舟云学术

Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2

Published:2013-03-24 Issue:6 Volume:104 Page:750-759
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Wang Shanshan¹,Zhu Yu²,He Hongyong³,Liu Jing⁴,Xu Le²,Zhang Heng³,Liu Haiou¹,Liu Weisi¹,Liu Yidong¹,Pan Deng¹,Chen Lin¹,Wu Qian¹,Xu Jiejie¹,Gu Jianxin¹

Affiliation:

1. Department of Biochemistry and Molecular Biology; School of Basic Medical Sciences; Shanghai; China

2. Department of Urology; Zhongshan Hospital; Shanghai Medical College; Fudan University; Shanghai; China

3. Department of General Surgery; Zhongshan Hospital; Shanghai Medical College; Fudan University; Shanghai; China

4. School of Medicine; Nantong University; Nantong; China

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.12132/fullpdf

Reference46 articles.

1. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

2. The role of signaling pathways in the development and treatment of hepatocellular carcinoma;Whittaker;Oncogene,2010

3. Hepatocellular carcinoma;Llovet;Lancet,2003

4. Opportunities for targeted therapies in hepatocellular carcinoma;Thomas;J Clin Oncol,2005

5. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2;Cancer Science;2024-04-16

2. Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic;eBioMedicine;2024-02

3. EZH2 Suppresses Ferroptosis in Hepatocellular Carcinoma and Reduces Sorafenib Sensitivity Through Epigenetic Regulation of TFR2;2023-09-15

4. SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma;iScience;2023-07

5. EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies;Experimental Hematology & Oncology;2023-06-02